Table 2.
Characteristics of Akita Mice during High-Dose Peptide Treatment (30 mg/kg Body Weight)
| Treatment | Body weight (g) | Blood glucose (mg/dL) | Systolic blood pressure (mmHg) | 24-hour urine volume (mL) |
|---|---|---|---|---|
| Before treatment | ||||
| Saline | 19.7 ± 1.0 (10) | 404 ± 110 (10) | 109 ± 6 (10) | 1.5 ± 0.5 (10) |
| LSKL | 20.8 ± 1.3 (10) | 375 ± 65 (10) | 105 ± 12 (10) | 2.2 ± 0.9 (10) |
| SLLK | 20.8 ± 1.2 (10) | 378 ± 56 (10) | 108 ± 10 (10) | 1.8 ± 0.5 (10) |
| 8 weeks of treatment | ||||
| Saline | 23.3 ± 2.2 (10) | 332 ± 80 (10) | 127 ± 5 (10) | 2.4 ± 0.7 (10) |
| LSKL | 23.0 ± 2.3 (9) | 373 ± 72 (10) | 133 ± 9 (10) | 3.0 ± 1.5 (10) |
| SLLK | 23.4 ± 1.4 (10) | 437 ± 80 (10) | 127 ± 6 (10) | 3.2 ± 1.1 (10) |
| 15 weeks of treatment | ||||
| Saline | 23.5 ± 2.2 (9) | 321 ± 114 (9) | 96 ± 7 (9) | 3.4 ± 0.8 (9) |
| LSKL | 23.0 ± 1.9 (9) | 353 ± 117 (9) | 94 ± 8 (9) | 3.2 ± 1.5 (9) |
| SLLK | 22.9 ± 2.0 (10) | 388 ± 137 (10) | 96 ± 8 (9) | 4.1 ± 1.6 (10) |
Data are given as mean ± SD. Values in parentheses are the number of animals tested per group.